第三条 利润分配原则为： （一）公司的利润分配应重视对投资者特别是中小投资者的合理投资回报， 并兼顾公司的可持续发展，保持利润分配政策的连续性和稳定性； （二）存在股东违规占用公司资金情况的，公司有权扣减该股东所分配的相 应金额现金红利，以偿还其占用的资金； （三）公司股利分配不得超过当年累计可分配利润的范围，不得损害公司 持续经营能力。 第一条 为规范南京药石科技股份有限公司（以下简称"公司"）的利润分 配行为，建立科学、持续、稳定的分配机制，增强利润分配的透明度，切实保 护中小投资者合法权益，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》《上市公司监管指引第 3 号——上市公司现金 分红（2023 年修订）》、《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规和规范性文件以及《南京药石科技股份 有限公司章程》（以下简称"《公司章程》"）的相关规定，以及中国证券监督管 理委员会（以下简称"中国证监会"）、深圳证券交易所的相关要求，并结合公 司实际情况，制定本制度。 第二条 公司将进一步强化回报股东的意识，严格依照《公司法》和《公司 ...

南京药石科技股份有限公司 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2024-083 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 1.公司非独立董事根据其在公司担任的实际工作岗位职务，按公司相关薪酬 标准与绩效考核领取薪酬，不额外领取董事津贴。未在公司担任实际工作岗位的 非独立董事，不在公司领取薪酬。 2.独立董事 关于第四届董事会、监事会成员薪酬方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）于2024年11月14日召开了 第三届董事会第三十八次会议、第三届监事会第二十二次会议，审议通过《关于 公司第四届董事会成员薪酬方案的议案》《关于公司第四届监事会成员薪酬方案 的议案》，相关议案尚需提交2024年第二次临时股东大会审议。具体情况公告如 下： 一、本方案适用对象 公司第四届董事会、第四届监事会全体成员 二、本方案适用期限 本次董事会、监事会薪酬方案自公司股东大会审议通过后生效，直至新的薪 酬方案通过后自动失效。 三、薪 ...

| 证券代码：300725 | 证券简称：药石科技 公告编号：2024-087 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 独立董事候选人声明与承诺 声明人金力作为南京药石科技股份有限公司第四届董事会独立董事候选 人，已充分了解并同意由提名人南京药石科技股份有限公司董事会提名为南京 药石科技股份有限公司（以下简称该公司）第四届董事会独立董事候选人。现 公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对 独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过南京药石科技股份有限公司第三届董事会提名委员会或 者独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影 响独立履职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 是 □ 否 如否，请详细说明：____________ ...

南京药石科技股份有限公司监事 会 | 证券代码：300725 | 证券简称：药石科技 公告编号：2024-082 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 关于监事会换届选举的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第三届监事会任期即将届 满，根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第2号—创业板上市公司规范运作》等法律法规、规范性 文件及《公司章程》的有关规定，公司开展监事会换届选举工作。 公司于2024年11月14日召开第三届监事会第二十二次会议，审议通过了《关 于公司监事会换届选举暨提名第四届监事会非职工代表监事候选人的议案》。公 司监事会提名李进先生、张树强先生为公司第四届监事会非职工代表监事候选人。 监事会对上述监事候选人的任职资格进行了审查，上述候选人均具备担任监事的 资格和能力，不存在《公司法》等相关法律法规规定的不得担任公司监事的情形， 最近两年内曾担任过公司董事或高级 ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - Short-term profitability is under pressure, but there is a positive trend in order growth, indicating long-term growth potential [2][3]. Financial Summary - Revenue for 2022 was 1,595 million, projected to be 1,725 million in 2023, with a decline to 1,570 million in 2024, followed by increases to 1,783 million in 2025 and 2,067 million in 2026 [1]. - Net profit attributable to the parent company was 314 million in 2022, expected to decrease to 197 million in 2023 and further to 186 million in 2024, before recovering to 221 million in 2025 and 271 million in 2026 [1]. - Earnings per share (EPS) is projected to be 0.99 in 2023, 0.93 in 2024, 1.11 in 2025, and 1.36 in 2026 [1]. - The return on equity (ROE) is expected to decline from 11.8% in 2022 to 7.0% in 2023, with a gradual recovery to 8.2% by 2026 [1]. Order and Market Trends - The company has seen a steady increase in order amounts, with a more than 20% year-on-year growth in orders as of the first half of 2024 [3]. - Active customer count reached 726, up 8.77% year-on-year, with 137 new customers added, marking a 34.31% increase [3]. - Revenue from large multinational corporations (MNCs) grew by 45.84%, accounting for 29% of total revenue [3]. Valuation and Price Target - The target price has been raised to 43.29 from the previous 31.25, based on a price-to-earnings (PE) ratio of 39 times for 2025 [5][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a steady growth in order backlog, with revenue recovering on a quarter-on-quarter basis [4] - Despite a year-on-year decline in revenue and net profit, the company maintains its profit forecast for 2024-2026 [4] - The company is actively expanding its overseas market presence, with new orders continuing to trend positively [5] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 1.128 billion yuan, a year-on-year decrease of 12.67%, and a net profit of 132 million yuan, down 14.45% [4] - In Q3 2024, the company reported revenue of 383 million yuan, a year-on-year decline of 14.39% but a quarter-on-quarter increase of 4.25% [4] - The company expects net profits for 2024-2026 to be 200 million, 238 million, and 280 million yuan respectively, with corresponding EPS of 1.00, 1.19, and 1.40 yuan [4] Order and Market Expansion - The company’s domestic revenue for the first three quarters of 2024 was 326 million yuan, down 22.67%, while international revenue was 802 million yuan, down 7.85% [5] - The order backlog increased by over 20% year-on-year in the first half of 2024, with new orders continuing to show positive trends in Q3 [5] - The company has established a subsidiary in Switzerland and integrated procurement systems with two of the top 10 global pharmaceutical companies, leading to a significant increase in order volume [5] CDMO Business Development - The revenue from drug research services for the first three quarters of 2024 was 253 million yuan, a decrease of 0.97%, while revenue from drug development and commercialization services was 874 million yuan, down 15.58% [6] - The company has expanded its project pipeline, with 1,200 projects in preclinical to Phase II and 35 projects in Phase III to commercialization as of H1 2024 [6] - Revenue from multinational corporations (MNCs) reached 216 million yuan in H1 2024, a year-on-year increase of 45.84%, accounting for 29.03% of total revenue [6]

Financial Performance - In Q3 2024, the company's revenue was 3.83 billion CNY, a year-on-year decrease of 14.39% [1] - For the first three quarters of 2024, total revenue was 11.28 billion CNY, down 12.67% year-on-year [1] - Revenue from drug research stage products and services was 2.53 billion CNY, a decline of 0.97% [1] - Revenue from drug development and commercialization stage products and services was 8.74 billion CNY, a decrease of 15.58% [1] - Domestic revenue was 3.26 billion CNY, down 22.67% year-on-year, while international revenue was 8.02 billion CNY, down 7.85% [1] - Net profit attributable to the parent company decreased mainly due to a decline in gross margin and exchange rate fluctuations [1] - Cash flow from operating activities was 1.89 billion CNY, an increase of 27.13% year-on-year [1] Order and Market Trends - The company reported a 20% year-on-year increase in the amount of orders on hand by the end of June [2] - Approximately 70% of the current orders are from clients in Europe and the United States, while 30% are from the Asia-Pacific region [2] - The company is experiencing a positive trend in new orders, particularly from multinational pharmaceutical clients [1] - The delivery cycle for early-stage projects is typically 4-5 months, while block projects take 2-3 months [2] Business Strategy and Development - The company is focusing on optimizing research and production processes to enhance delivery efficiency and drive business growth [1] - There is an ongoing recruitment of talented personnel to support business needs, with a slight increase in staff numbers by the end of Q3 [3] - The company is expanding its molecular building block product offerings, including new chemical entities like targeted protein degradation (TPD) and peptides [2] - The company has entered three multinational pharmaceutical procurement systems to facilitate client access to its molecular building block products [3] Financial Management and Outlook - The company has maintained stable expense ratios, with cash flow management being a priority to improve cash flow quality [4] - The increase in inventory is primarily due to the accumulation of orders, with most expected to be delivered within the year [3] - The company anticipates a gradual increase in orders to be delivered in the first half of the following year [3] - Emerging businesses, such as ADC and oligonucleotides, have shown rapid growth, with revenue doubling compared to the previous year [5]

新增 2024 年度日常关联交易预计的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"、"保荐机构"）作为南 京药石科技股份有限公司（以下简称"药石科技"、"公司"）2022 年度向不特定 对象发行可转换公司债券的保荐机构，根据《深圳证券交易所创业板股票上市规 则》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《深 圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等有关 法律法规规定，对药石科技新增 2024 年度日常关联交易预计事项进行了核查， 具体如下： 华泰联合证券有限责任公司 关于南京药石科技股份有限公司 一、日常关联交易基本情况 （一）前期已预计 2024 年度日常关联交易情况 南京药石科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 第三届董事会第三十次会议、第三届监事会第十八次会议，审议通过了《关于 2023 年度日常关联交易确认及 2024 年度日常关联交易额度预计的议案》，公司 及子公司因业务发展的需要，预计 2024 年度公司可能发生的关联交易不超过 6,570 万元。 （二）本次增加的日常关联交易预计情况 1 二 ...

Financial Performance - The company's revenue for Q3 2024 was ¥383,025,884.53, a decrease of 14.39% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 was ¥33,099,319.24, down 17.57% year-on-year[1] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥20,117,133.75, a significant decline of 58.16% compared to the previous year[1] - The basic earnings per share for Q3 2024 was ¥0.1664, down 17.26% year-on-year[1] - The net profit for Q3 2024 was CNY 131,790,818.60, a decrease of 14.4% compared to CNY 154,046,255.25 in Q3 2023[14] - Operating profit for Q3 2024 was CNY 137,531,895.14, slightly down from CNY 137,936,719.39 in the same period last year[14] - The total comprehensive income for Q3 2024 was CNY 130,726,069.30, down from CNY 156,901,390.33 in Q3 2023, representing a decline of 16.7%[14] - Basic earnings per share for Q3 2024 were CNY 0.6626, compared to CNY 0.7715 in the same quarter last year, a decrease of 14.1%[14] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥4,915,519,528.69, reflecting a decrease of 3.69% from the end of the previous year[1] - The company's total assets decreased to approximately 4.916 billion CNY from 5.104 billion CNY at the beginning of the period[12] - The total liabilities decreased to approximately 2.015 billion CNY from 2.272 billion CNY at the beginning of the period[12] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥188,877,638.63, an increase of 27.13% compared to the same period last year[1] - The net cash flow from operating activities was 189 million CNY, an increase of 27.13% year-on-year[9] - Cash recovered from investments rose by 79.48%, reaching ¥2,734,421,639.56, attributed to an increase in redeemed financial products[5] - Cash received from investment income increased by 53.11%, totaling ¥32,015,910.36, reflecting higher returns from financial investments[5] - Cash flow from operating activities netted CNY 188,877,638.63, up from CNY 148,570,068.07 in the previous year, indicating a 27% increase[17] - Cash flow from investment activities showed a net outflow of CNY 5,986,725.75, an improvement from a net outflow of CNY 453,085,157.78 in Q3 2023[18] - Cash flow from financing activities resulted in a net outflow of CNY 377,079,879.92, compared to a net inflow of CNY 206,338,439.86 in the same quarter last year[18] Revenue Breakdown - For the first three quarters of 2024, total revenue reached 1.128 billion CNY, down 12.67% year-on-year[9] - Revenue from drug research stage products and services was 253 million CNY, a slight decrease of 0.97% year-on-year, while revenue from drug development and commercialization stage products and services was 874 million CNY, down 15.58% year-on-year[9] - Domestic revenue was 326 million CNY, down 22.67% year-on-year, while international revenue was 802 million CNY, down 7.85% year-on-year[9] - Total revenue from operating activities increased to CNY 1,278,208,259.42, compared to CNY 1,258,185,266.27 in Q3 2023, reflecting a growth of 1.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 32,367[6] - The largest shareholder, Yang Minmin, holds 20.74% of the shares, totaling 41,403,319 shares, with 12,500,000 shares pledged[6] Expenses and Investments - Research and development expenses for the year-to-date were ¥88,967,345.69, a decrease of 32.87% compared to the previous year[4] - Tax payments increased by 73.44%, amounting to ¥73,627,376.80, primarily due to higher income and value-added tax payments[5] - Cash paid for the acquisition of fixed assets decreased by 74.96%, amounting to ¥73,830,708.13, due to reduced construction investments[5] - Cash paid for investments increased by 57.79%, totaling ¥2,687,903,747.90, as the company purchased more financial products[5] - Cash paid for debt repayment surged by 98.58%, reaching ¥538,760,300.00, due to an increase in repaid bank loans[5] - Cash dividends and interest payments increased by 105.93%, totaling ¥76,714,938.48, reflecting higher cash dividend payments[5] Operational Efficiency - The company's gross profit margin declined, contributing to a decrease in net profit attributable to the parent company[9] - The company continues to optimize its R&D and production processes to enhance delivery efficiency and drive business growth[9] - The company has maintained stable expense ratios across various categories during the reporting period[9]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2024-074 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司（以下简称"公司"）第三届董事会第三十七次 会议于2024年10月29日以现场结合视频会议形式在公司会议室召开，以书面方式 进行表决。会议通知已于2024年10月25日通过电子邮件等方式送达各位董事。会 议由董事长杨民民先生召集主持，应出席董事人数7人，实际出席董事人数7人。 公司部分高级管理人员列席会议。本次会议的召集、召开符合《中华人民共和国 公司法》和《南京药石科技股份有限公司公司章程》等有关规定。 一、 董事会会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 1、审议通过了《关于公司<2024 年第三季度报告>的议案》。 经审核，董事会认为：公司 2024 年第三季度报告的编制程序符合法律、行 政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经第三届董事会审计委员会 2024 ...